cstone pharmaceuticals co ltd - CSPHF

CSPHF

Close Chg Chg %
0.88 0.13 15.10%

Open Market

1.01

+0.13 (15.10%)

Volume: 105.00

Last Updated:

Mar 27, 2026, 9:30 AM EDT

Company Overview: cstone pharmaceuticals co ltd - CSPHF

CSPHF Key Data

Open

$1.01

Day Range

1.01 - 1.01

52 Week Range

0.52 - 1.01

Market Cap

$1.49B

Shares Outstanding

1.47B

Public Float

1.06B

Beta

-0.76

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.05

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

N/A

 

CSPHF Performance

1 Week
 
0.00%
 
1 Month
 
43.69%
 
3 Months
 
94.94%
 
1 Year
 
1.00%
 
5 Years
 
N/A
 

CSPHF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About cstone pharmaceuticals co ltd - CSPHF

Cstone Pharmaceuticals Co. Ltd. is an investment holding company, which engages in the research and development of complex biopharmaceutical products and sale of pharmaceutical products. Its products include immuno-oncology drugs and molecularly targeted drugs. The company was founded on December 2, 2015, and is headquartered in Shanghai, China.

CSPHF At a Glance

CStone Pharmaceuticals Co. Ltd.
North Block Suzhou Industrial Park
Shanghai, Shanghai 200126
Phone 86-21-6109-7678 Revenue 37.50M
Industry Pharmaceuticals: Major Net Income -60,792,398.61
Sector Health Technology Employees 93
Fiscal Year-end 12 / 2026
View SEC Filings

CSPHF Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 25.066
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -15.878
Enterprise Value to Sales 22.891
Total Debt to Enterprise Value 0.058

CSPHF Efficiency

Revenue/Employee 403,250.035
Income Per Employee -653,681.706
Receivables Turnover 7.751
Total Asset Turnover 0.195

CSPHF Liquidity

Current Ratio 2.182
Quick Ratio 1.953
Cash Ratio 1.801

CSPHF Profitability

Gross Margin 17.054
Operating Margin -160.478
Pretax Margin -157.257
Net Margin -162.103
Return on Assets -31.557
Return on Equity -88.035
Return on Total Capital -44.01
Return on Invested Capital -61.855

CSPHF Capital Structure

Total Debt to Total Equity 56.507
Total Debt to Total Capital 36.105
Total Debt to Total Assets 25.657
Long-Term Debt to Equity 25.444
Long-Term Debt to Total Capital 16.257
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cstone Pharmaceuticals Co Ltd - CSPHF

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
71.49M 65.47M 56.58M 37.50M
Sales Growth
+89.17% -8.42% -13.57% -33.72%
Cost of Goods Sold (COGS) incl D&A
33.32M 25.21M 30.12M 31.11M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
8.17M 8.21M 6.92M 6.12M
Depreciation
6.29M 6.16M 5.30M 4.49M
Amortization of Intangibles
1.88M 2.05M 1.62M 1.62M
COGS Growth
+73.04% -24.34% +19.49% +3.28%
Gross Income
38.17M 40.26M 26.46M 6.40M
Gross Income Growth
+105.92% +5.48% -34.27% -75.83%
Gross Profit Margin
+53.39% +61.50% +46.77% +17.05%
2022 2023 2024 2025 5-year trend
SG&A Expense
173.63M 125.73M 39.71M 66.58M
Research & Development
91.21M 74.49M 11.73M 43.33M
Other SG&A
82.42M 51.24M 27.98M 23.24M
SGA Growth
-42.55% -27.59% -68.42% +67.66%
Other Operating Expense
- - - -
-
Unusual Expense
9.20M (42.48K) 607.21K 98.07K
EBIT after Unusual Expense
(144.66M) (85.43M) (13.86M) (60.28M)
Non Operating Income/Expense
11.86M 35.26M 3.29M 3.15M
Non-Operating Interest Income
1.44M 3.51M 1.76M 1.44M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.26M 1.67M 2.11M 1.85M
Interest Expense Growth
+262.13% +32.51% +26.33% -12.39%
Gross Interest Expense
1.75M 1.67M 2.11M 1.85M
Interest Capitalized
- - - 494.68K
-
Pretax Income
(134.05M) (51.83M) (12.67M) (58.98M)
Pretax Income Growth
+54.97% +61.33% +75.55% -365.35%
Pretax Margin
-187.53% -79.17% -22.40% -157.26%
Income Tax
- - - 1.82M
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(134.05M) (51.83M) (12.67M) (60.79M)
Minority Interest Expense
- - - -
-
Net Income
(134.05M) (51.83M) (12.67M) (60.79M)
Net Income Growth
+54.97% +61.33% +75.55% -379.69%
Net Margin Growth
-187.53% -79.17% -22.40% -162.10%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(134.05M) (51.83M) (12.67M) (60.79M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(134.05M) (51.83M) (12.67M) (60.79M)
EPS (Basic)
-0.1143 -0.041 -0.0099 -0.0438
EPS (Basic) Growth
+55.26% +64.13% +75.85% -342.42%
Basic Shares Outstanding
1.17B 1.26B 1.28B 1.39B
EPS (Diluted)
-0.1143 -0.041 -0.0099 -0.0438
EPS (Diluted) Growth
+55.26% +64.13% +75.85% -342.42%
Diluted Shares Outstanding
1.17B 1.26B 1.28B 1.39B
EBITDA
(127.29M) (77.26M) (6.33M) (54.06M)
EBITDA Growth
+54.56% +39.31% +91.81% -754.19%
EBITDA Margin
-178.07% -118.01% -11.19% -144.16%

Cstone Pharmaceuticals Co Ltd in the News